Screening of an annexin-A2-targeted heptapeptide for pancreatic adenocarcinoma localization.
ANXA2
imaging
near-infrared fluorescent
pancreatic adenocarcinoma
peptide
Journal
Molecular oncology
ISSN: 1878-0261
Titre abrégé: Mol Oncol
Pays: United States
ID NLM: 101308230
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
revised:
04
11
2022
received:
11
08
2022
accepted:
30
11
2022
medline:
8
5
2023
pubmed:
2
12
2022
entrez:
1
12
2022
Statut:
ppublish
Résumé
Annexin A2 (ANXA2) encodes an oncoprotein whose expression has been found to correlate with poorer overall survival (OS) of pancreatic adenocarcinoma (PAAD) patients. Although peptides are available for targeting ANXA2, none of these were initially selected to target this protein specifically. Here, we took ANXA2 as a molecular target for PAAD and employed the phage display technique to screen for a new ANXA2-targeted peptide. The resultant heptapeptide, YW7, was firstly labeled with fluorescein isothiocyanate (FITC) to evaluate its selectivity in cellular uptake, and further with the near-infrared fluorescent (NIRF) dye Cy7 to assess in vivo distribution in a mouse model bearing PANC-1 human pancreatic cancer xenografic tumors. We found that both FITC-YW7 and Cy7-YW7 probes showed significantly higher uptake in PANC-1 cells compared to the HPDE6-C7 pancreatic epithelium cells. Mice intravenously injected with Cy7-YW7 showed higher tumor-to-background ratios (TBRs) (~ 2.7-fold) in tumor tissues compared to those injected with Cy7 alone. Our study suggested that YW7 is a novel peptide targeting ANXA2 and Cy7-YW7 is an NIRF probe potentially useful for the early detection of PAAD.
Identifiants
pubmed: 36453020
doi: 10.1002/1878-0261.13352
pmc: PMC10158761
doi:
Substances chimiques
Annexin A2
0
Fluorescein-5-isothiocyanate
I223NX31W9
Peptides
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
872-886Informations de copyright
© 2022 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
Références
J Biol Chem. 2010 Feb 12;285(7):4366-74
pubmed: 20018898
Expert Rev Anticancer Ther. 2018 Sep;18(9):837-860
pubmed: 29973077
Pancreas. 2018 Jul;47(6):675-689
pubmed: 29894417
Ann N Y Acad Sci. 1998 Feb 9;838:29-45
pubmed: 9511793
Surgery. 2019 Aug;166(2):150-156
pubmed: 31171367
J Cancer Res Ther. 2020 Dec;16(Supplement):S110-S115
pubmed: 33380663
Lancet Gastroenterol Hepatol. 2020 Jul;5(7):698-710
pubmed: 32135127
Hematol Oncol Clin North Am. 2015 Aug;29(4):701-16
pubmed: 26226905
Cell Chem Biol. 2016 Jan 21;23(1):122-136
pubmed: 26933740
J Clin Invest. 2019 Feb 1;129(2):616-630
pubmed: 30457978
Int J Mol Sci. 2013 Mar 19;14(3):6259-305
pubmed: 23519104
Cells. 2020 Jun 19;9(6):
pubmed: 32575495
Mol Biotechnol. 2019 Apr;61(4):286-303
pubmed: 30729435
Eur Urol. 2011 Oct;60(4):826-33
pubmed: 21458154
Nat Biomed Eng. 2020 Mar;4(3):298-313
pubmed: 32165732
Contrast Media Mol Imaging. 2018 Aug 27;2018:2015237
pubmed: 30224903
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Cancer J. 2017 Nov/Dec;23(6):333-342
pubmed: 29189329
J Surg Res. 2019 Jul;239:44-51
pubmed: 30798171
ACS Nano. 2015 Aug 25;9(8):7976-91
pubmed: 26242412
Curr Pharm Des. 2011 Dec;17(38):4362-71
pubmed: 22204434
Cancer Biol Med. 2019 Nov;16(4):671-687
pubmed: 31908887
Bioorg Med Chem. 2018 Jun 1;26(10):2816-2826
pubmed: 29042225
Anticancer Agents Med Chem. 2018;18(1):74-86
pubmed: 28425855
Adv Exp Med Biol. 2020;1296:243-257
pubmed: 34185297
Methods Enzymol. 2008;445:83-106
pubmed: 19022056